Dongsheng Competitors

Delisted . USA . 
Stock . Dongsheng Pharmaceutical International
Dongsheng Pharmaceutical competes with AmTrust Financial, Park National, Univest Pennsylvania, Neogen, and Siriuspoint; as well as few others. Analyzing Dongsheng Pharmaceutical competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Dongsheng Pharmaceutical to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Dongsheng Pharmaceutical competition on your existing holdings.
  
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Dongsheng Pharmaceutical's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.000.000.00
Details
Intrinsic
Valuation
LowRealHigh
0.000.000.00
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Dongsheng Pharmaceutical. Your research has to be compared to or analyzed against Dongsheng Pharmaceutical's peers to derive any actionable benefits. When done correctly, Dongsheng Pharmaceutical's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Dongsheng Pharmaceutical.

Dongsheng Pharmaceutical Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Dongsheng Pharmaceutical and its competitors represents the degree of relationship between the price movements of corresponding otcs. A correlation of about +1.0 implies that the price of Dongsheng and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Dongsheng Pharmaceutical does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
TFX
+ 0.93
SSY
DFS
+ 0.79
AFSIP
UVSP
+ 0.78
PRK
TFX
+ 0.67
NEOG
SSY
+ 0.66
NEOG
DFS
+ 0.66
SPNT
  
High negative correlations   
SSY
- 0.9
AFSIP
SSY
- 0.88
DFS
TFX
- 0.86
AFSIP
TFX
- 0.79
DFS
NEOG
- 0.67
AFSIP
SSY
- 0.6
SPNT

Risk-Adjusted Indicators

There is a big difference between Dongsheng OTC BB Equity performing well and Dongsheng Pharmaceutical Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Dongsheng Pharmaceutical's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

Dongsheng Pharmaceutical Competitive Analysis

The better you understand Dongsheng Pharmaceutical competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Dongsheng Pharmaceutical's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Dongsheng Pharmaceutical's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
AFSIP PRK UVSP NEOG SPNT DFS SSY TFX
 0.23 
 13.36 
AmTrust
 2.19 
 128.01 
Park
 4.57 
 19.44 
Univest
 2.68 
 11.61 
Neogen
 0.33 
 12.02 
Siriuspoint
 0.87 
 125.35 
Discover
 1.45 
 0.68 
SunLink
 0.40 
 206.56 
Teleflex
Market Volatility
(90 Days Market Risk)
Not too volatile
Very steady
Very steady
Not too volatile
Not too volatile
Very steady
Dangerous
Very steady
Market Performance
(90 Days Performance)
OK
Very Weak
Very Weak
Very Weak
Insignificant
Good
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
High
Very Low
Very Low
Below Average
Low
Below Average
Low
Very Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Under Valued
Under Valued
Fairly Valued
Fairly Valued
Over Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Hold
Hold
Buy
Strong Sell
Buy
Not Available
Buy
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Hold
Strong Hold
Hold
Strong Hold
Buy
Strong Sell
Strong Hold
Current Ratio
1.62 X
N/A
N/A
9.07 X
3.31 X
1.24 X
2.19 X
2.39 X
Net Asset
25.22 B
9.84 B
7.8 B
4.55 B
10.13 B
151.61 B
23.27 M
7.53 B
Profit Margin
0.04 %
0.27 %
0.25 %
0 %
0.13 %
0.23 %
(0.14) %
0.12 %
EBITDA
(284.69 M)
15.32 M
938 K
125.89 M
(8.9 M)
168 M
(587 K)
817.61 M
Operating Margin
(0.07) %
0.29 %
0.32 %
0.05 %
0.07 %
0.12 %
(0.05) %
0.13 %
Current Valuation
5.69 B
2.33 B
804.73 M
3.37 B
1.19 B
23.58 B
3.47 M
11.62 B
Price To Book
N/A
1.76 X
0.66 X
0.85 X
0.90 X
2.20 X
0.37 X
2.27 X
Retained Earnings
N/A
903.88 M
474.69 M
565.04 M
601 M
30.45 B
3 M
4.11 B
Current Asset
N/A
N/A
N/A
250 M
N/A
120.27 M
17.89 M
1 B
Five Year Return
11.24 %
3.82 %
3.30 %
N/A
N/A
2.14 %
N/A
0.44 %
Beta
0.62
0.7
0.89
1.12
0.94
1.44
1.36
1.12
Number Of Employees
9.3 K
1.65 K
920
2.64 K
999
21.1 K
N/A
14.5 K
Shares Outstanding
N/A
16.12 M
29.53 M
216.61 M
169.78 M
250.56 M
7.04 M
47.1 M
Cash Flow From Operations
(375.3 M)
258.25 M
91.77 M
41.03 M
581.3 M
8.56 B
(540 K)
510.64 M
Annual Yield
0.12 %
0.03 %
0.05 %
N/A
N/A
0.02 %
N/A
0.01 %
Total Debt
1.46 B
533.93 M
499.92 M
900 M
786.2 M
21.33 B
1.08 M
1.93 B
Return On Equity
0.0707
0.11
0.088
5.0E-4
0.16
0.16
-0.26
0.0845
Z Score
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
-0.0108
0.0129
0.0095
0.0179
0.0232
0.016
-0.14
0.0434
Book Value Per Share
12.60 X
71.06 X
28.44 X
14.53 X
13.76 X
58.88 X
1.85 X
94.41 X
Number Of Shares Shorted
N/A
638.88 K
217.65 K
16.71 M
2.21 M
2.83 M
22.84 K
888.21 K
Current Liabilities
N/A
N/A
N/A
28.6 M
N/A
171 M
20.05 M
664.12 M
Total Asset
25.22 B
9.84 B
7.8 B
4.55 B
10.13 B
151.61 B
23.27 M
7.53 B
Debt To Equity
0.50 %
9.25 %
0.14 %
0 %
0.37 %
1.41 %
0.07 %
0.46 %
Last Dividend Paid
0.34
4.2
0.84
N/A
N/A
2.8
N/A
1.36
Short Ratio
N/A
14.01 X
2.51 X
12.78 X
3.54 X
1.66 X
5.82 X
3.10 X
Target Price
N/A
128.67
21.33
17.0
N/A
133.31
2.35
264.5
Shares Owned By Institutions
N/A
54.20 %
76.76 %
99.86 %
86.56 %
89.22 %
14.86 %
98.54 %
Market Capitalization
N/A
2.02 B
548.94 M
2.63 B
2.03 B
31.14 B
4.86 M
9.9 B
Price To Earning
16.38 X
15.88 X
11.33 X
13.36 X
3.25 X
7.05 X
3.06 X
38.28 X
Price To Earnings To Growth
N/A
4.82 X
4.47 X
0.66 X
(0.25) X
3.28 X
N/A
2.48 X
Price To Sales
N/A
4.36 X
1.93 X
2.89 X
0.76 X
3.08 X
0.10 X
3.40 X
Net Income
(348.89 M)
126.73 M
71.1 M
(22.87 M)
363.7 M
2.92 B
(1.79 M)
356.33 M
Earnings Per Share
0.98 X
7.80 X
2.41 X
0.02 X
1.85 X
8.79 X
(0.60) X
7.56 X
Shares Owned By Insiders
N/A
2.63 %
1.77 %
0.14 %
10.20 %
0.55 %
26.92 %
0.25 %
Revenue
5.82 B
574.69 M
447.25 M
822.45 M
2.74 B
20.61 B
47.95 M
2.97 B
Working Capital
N/A
N/A
N/A
440.46 M
N/A
(50.73 M)
7.41 M
800.66 M
Cash And Equivalents
756.1 M
209.06 M
113.98 M
347.71 M
4.34 B
10 B
4.49 M
292.03 M
Cash Per Share
3.82 X
12.85 X
3.90 X
3.22 X
27.15 X
36.61 X
0.97 X
9.08 X
Gross Profit
872.65 M
478.44 M
283.98 M
409.2 M
(129.2 M)
10.46 B
4.71 M
1.55 B
Day Typical Price
13.39
126.85
19.13
11.75
12.05
125.1
0.69
206.91
Accumulation Distribution
32.1
2083.29
3907.87
95149.3
10402.15
28847.07
61.17
7255.8
Market Facilitation Index
1.0E-4
1.0E-4
0.0
N/A
N/A
0.0
0.0
0.0
Daily Balance Of Power
0.1304
0.5469
0.8673
(0.52)
0.1818
0.4596
(0.50)
(0.23)
Period Momentum Indicator
0.03
2.74
0.85
(0.32)
0.04
1.08
(0.01)
(0.82)
Rate Of Daily Change
1.0
1.02
1.05
0.97
1.0
1.01
0.99
1.0
Day Median Price
13.41
126.27
18.98
11.82
12.06
124.98
0.69
207.08
Price Action Indicator
(0.03)
3.11
0.89
(0.37)
(0.02)
0.91
(0.01)
(0.93)
Coefficient Of Variation
1019.99
8584.14
(2,562)
(448.52)
1248.69
1101.29
(517.57)
(671.33)
Mean Deviation
0.9923
1.28
1.48
1.92
1.24
1.49
1.62
1.23
Jensen Alpha
0.1614
(0.09)
(0.20)
(0.74)
0.0894
0.1727
(0.38)
(0.33)
Total Risk Alpha
(0)
(0.16)
(0.28)
(0.85)
(0.04)
(0.02)
(0.62)
(0.41)
Sortino Ratio
0.0401
(0.02)
N/A
N/A
0.0412
0.0644
N/A
N/A
Downside Variance
4.42
4.84
N/A
N/A
3.67
6.24
N/A
N/A
Standard Deviation
1.56
1.85
2.04
2.63
1.84
2.53
2.13
1.63
Kurtosis
2.49
3.26
0.8016
1.46
5.87
13.02
1.16
0.9871
Potential Upside
2.69
2.71
3.9
3.29
2.96
3.06
2.67
2.4
Treynor Ratio
(0.45)
0.0065
(0.05)
(0.24)
0.1676
0.275
0.6256
(0.18)
Maximum Drawdown
7.8
9.82
10.2
15.48
14.48
15.51
12.75
8.62
Variance
2.43
3.41
4.16
6.91
3.39
6.39
4.56
2.65
Market Risk Adjusted Performance
(0.44)
0.0165
(0.04)
(0.23)
0.1776
0.285
0.6356
(0.17)
Risk Adjusted Performance
0.0666
0.0139
(0.02)
(0.13)
0.0561
0.0637
(0.11)
(0.09)
Skewness
0.4481
(1.16)
(0.07)
(0.44)
(0.09)
0.5802
(0.03)
(0.09)
Semi Deviation
1.16
2.16
N/A
N/A
1.69
2.24
N/A
N/A
Information Ratio
0.0541
(0.03)
(0.07)
(0.25)
0.0428
0.0637
(0.23)
(0.19)
Value At Risk
(2.21)
(3.42)
(3.71)
(4.77)
(2.09)
(2.43)
(3.95)
(2.46)
Expected Short fall
(1.41)
(1.19)
N/A
N/A
(1.31)
(1.54)
N/A
N/A
Downside Deviation
2.1
2.2
N/A
N/A
1.92
2.5
N/A
N/A
Semi Variance
1.35
4.65
N/A
N/A
2.86
5.03
N/A
N/A

Dongsheng Pharmaceutical Competition Performance Charts

Five steps to successful analysis of Dongsheng Pharmaceutical Competition

Dongsheng Pharmaceutical's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Dongsheng Pharmaceutical in relation to its competition. Dongsheng Pharmaceutical's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Dongsheng Pharmaceutical in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Dongsheng Pharmaceutical's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Dongsheng Pharmaceutical, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Dongsheng Pharmaceutical position

In addition to having Dongsheng Pharmaceutical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Health Management Thematic Idea Now

Health Management
Health Management Theme
Major hospitals and healthcare providers. The Health Management theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Health Management Theme or any other thematic opportunities.
View All  Next Launch
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
Note that the Dongsheng Pharmaceutical information on this page should be used as a complementary analysis to other Dongsheng Pharmaceutical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Consideration for investing in Dongsheng OTC BB Equity

If you are still planning to invest in Dongsheng Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Dongsheng Pharmaceutical's history and understand the potential risks before investing.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY